- Home
- GRFS vs DYN Comparison
GRFS vs DYN Comparison
Compare GRFS & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GRFS | DYN |
|---|---|---|
| Founded | 1940 | 1984 |
| Country | Spain | United States |
| Employees | 25247 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 3.9B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | GRFS | DYN |
|---|---|---|
| Price | $7.64 | $24.57 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 14 |
| Target Price | $10.15 | ★ $37.00 |
| AVG Volume (30 Days) | 647.2K | ★ 2.6M |
| Earning Date | 07-28-2022 | 05-04-2026 |
| Dividend Yield | ★ 1.80% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.49 | N/A |
| Revenue Next Year | $6.42 | N/A |
| P/E Ratio | $18.67 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.96 | $8.88 |
| 52 Week High | $11.14 | $25.00 |
Technical Indicators
Market Signals| Indicator | GRFS | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 55.96 | 63.30 |
| Support Level | $7.64 | $16.47 |
| Resistance Level | $7.73 | $24.52 |
| Average True Range (ATR) | 0.16 | 1.46 |
| MACD | 0.07 | -0.11 |
| Stochastic Oscillator | 68.62 | 84.68 |
Price Performance
Historical ComparisonAbout GRFS Grifols S.A.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.